Related Experiment Video

Updated: May 24, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Effect of shRNA targeting survivin on ovarian cancer

Jun Xing1, Chang-Ru Jia, Yan Wang

  • 1Department of Gastrointestinal Surgery, The Third Hospital of Harbin Medical University, No. 150, Ha Ping Road, Nan Gang District, Heilongjiang Province, People's Republic of China.

Journal of Cancer Research and Clinical Oncology
|March 20, 2012
PubMed
Abstract

Insights

Short hairpin RNA (shRNA) targeting survivin effectively reduced ovarian cancer cell growth and survivin expression in cell cultures and xenografts. This suggests shRNA targeting survivin is a promising therapeutic strategy for ovarian cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Survivin is a key protein involved in cell survival and proliferation, often overexpressed in various cancers, including ovarian cancer.
  • Targeting survivin offers a potential strategy for inhibiting cancer cell growth and inducing apoptosis.

Purpose of the Study:

  • To investigate the efficacy of short hairpin RNA (shRNA) targeting survivin in ovarian cancer.
  • To evaluate the impact of survivin inhibition on ovarian cancer cell behavior in vitro and in vivo.

Main Methods:

  • Transfection of SKOV3 ovarian cancer cells with survivin-targeting shRNA.
  • Assessment of survivin expression, apoptosis (using TEM, flow cytometry, TUNEL), and cell proliferation (MTT assay).
  • Evaluation of tumor growth inhibition in a murine ovarian cancer xenograft model treated with survivin-targeting shRNA.

Main Results:

  • Survivin-targeting shRNA significantly increased apoptosis and reduced proliferation in SKOV3 cells.
  • Reduced survivin expression was observed at the molecular level in treated cells.
  • In vivo, shRNA treatment markedly inhibited ovarian cancer xenograft growth with no apparent side effects.

Conclusions:

  • shRNA targeting survivin demonstrates significant potential as a therapeutic agent for ovarian cancer.
  • Inhibition of survivin through shRNA is a viable strategy for controlling ovarian cancer progression.

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...